Evidence map›Paper›PMID 35877677›Full record

SynthesisPLoS medicine2022

Implementation research on noncommunicable disease prevention and control interventions in low- and middle-income countries: A systematic review.

Celestin Hategeka, Prince Adu, Allissa Desloge, Robert Marten, Ruitai Shao, Maoyi Tian, Ting Wei, Margaret E Kruk

Abstract readSystematic Review
In one paragraph

Synthesis in PLoS medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Celestin HategekaDepartment of Global Health and Population, Harvard TH Chan School of Public Health, Boston, Massachusetts, United States of America.ORCID 0000-0001-7808-4652
Prince AduSchool of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.ORCID 0000-0002-3983-0875
Allissa DeslogeSchool of Public Health, University of Illinois Chicago, Chicago, Illinois, United States of America.ORCID 0000-0001-8480-7335
Robert MartenAlliance for Health Policy and Systems Research, WHO, Geneva, Switzerland.
Ruitai ShaoDepartment of NCD, WHO, Geneva, Switzerland.ORCID 0000-0003-1977-7445
Maoyi TianThe George Institute for Global Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia.ORCID 0000-0002-5660-8571
Ting WeiThe George Institute for Global Health, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia.
Margaret E KrukDepartment of Global Health and Population, Harvard TH Chan School of Public Health, Boston, Massachusetts, United States of America.ORCID 0000-0002-9549-8432

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundWhile the evidence for the clinical effectiveness of most noncommunicable disease (NCD) prevention and treatment interventions is well established, care delivery models and means of scaling these up in a variety of resource-constrained health systems are not. The objective of this review was to synthesize evidence on the current state of implementation research on priority NCD prevention and control interventions provided by health systems in low- and middle-income countries (LMICs). METHODS AND

findingsOn January 20, 2021, we searched MEDLINE and EMBASE databases from 1990 through 2020 to identify implementation research studies that focused on the World Health Organization (WHO) priority NCD prevention and control interventions targeting cardiovascular disease, cancer, diabetes, and chronic respiratory disease and provided within health systems in LMICs. Any empirical and peer-reviewed studies that focused on these interventions and reported implementation outcomes were eligible for inclusion. Given the focus on this review and the heterogeneity in aims and methodologies of included studies, risk of bias assessment to understand how effect size may have been compromised by bias is not applicable. We instead commented on the distribution of research designs and discussed about stronger/weaker designs. We synthesized extracted data using descriptive statistics and following the review protocol registered in PROSPERO (CRD42021252969). Of 9,683 potential studies and 7,419 unique records screened for inclusion, 222 eligible studies evaluated 265 priority NCD prevention and control interventions implemented in 62 countries (6% in low-income countries and 90% in middle-income countries). The number of studies published has been increasing over time. Nearly 40% of all the studies were on cervical cancer. With regards to intervention type, screening accounted for 49%, treatment for 39%, while prevention for 12% (with 80% of the latter focusing on prevention of the NCD behavior risk factors). Feasibility (38%) was the most studied implementation outcome followed by adoption (23%); few studies addressed sustainability. The implementation strategies were not specified well enough. Most studies used quantitative methods (86%). The weakest study design, preexperimental, and the strongest study design, experimental, were respectively employed in 25% and 24% of included studies. Approximately 72% of studies reported funding, with international funding being the predominant source. The majority of studies were proof of concept or pilot (88%) and targeted the micro level of health system (79%). Less than 5% of studies report using implementation research framework.

conclusionsDespite growth in implementation research on NCDs in LMICs, we found major gaps in the science. Future studies should prioritize implementation at scale, target higher levels health systems (meso and macro levels), and test sustainability of NCD programs. They should employ designs with stronger internal validity, be more conceptually driven, and use mixed methods to understand mechanisms. To maximize impact of the research under limited resources, adding implementation science outcomes to effectiveness research and regional collaborations are promising.

Indexed as

Noncommunicable DiseasesDeveloping CountriesHealth ServicesHumansIncomePoverty

Identifiers

PMID35877677
PMCPMC9359585

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.